TigerOak Management L.L.C. Takes $522,000 Position in Eli Lilly and Company (NYSE:LLY)

TigerOak Management L.L.C. purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 676 shares of the company’s stock, valued at approximately $522,000.

Several other large investors have also recently bought and sold shares of the stock. Highland Financial Advisors LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at about $792,000. Roxbury Financial LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at about $87,000. Members Trust Co raised its holdings in Eli Lilly and Company by 4.1% in the 4th quarter. Members Trust Co now owns 427 shares of the company’s stock valued at $330,000 after acquiring an additional 17 shares during the period. Aveo Capital Partners LLC raised its holdings in Eli Lilly and Company by 7.0% in the 4th quarter. Aveo Capital Partners LLC now owns 1,730 shares of the company’s stock valued at $1,335,000 after acquiring an additional 113 shares during the period. Finally, Manchester Capital Management LLC raised its holdings in Eli Lilly and Company by 17.3% in the 4th quarter. Manchester Capital Management LLC now owns 5,516 shares of the company’s stock valued at $4,258,000 after acquiring an additional 812 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on LLY shares. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Barclays decreased their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Finally, Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $997.50.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $844.82 on Monday. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a market capitalization of $802.01 billion, a P/E ratio of 72.15, a P/E/G ratio of 1.87 and a beta of 0.42. The company’s 50 day moving average price is $794.44 and its two-hundred day moving average price is $844.98.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. On average, equities analysts forecast that Eli Lilly and Company will post 23.33 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.71%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 44.41%.

Eli Lilly and Company declared that its board has initiated a stock buyback plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.